Trial intelligence / Profile preview

Safety and Immunogenicity of Trumenba and Repevax Co-administration in Adolescents

NCT01323270Phase 2Completed

Sponsor
Pfizer
Start
Mar 2011
Primary completion
Oct 2012
Modality
Vaccines & Immunotherapeutics
Countries
3
01

Overview

A Phase 2 trial of meningococcal group B vaccine in meningococcal disease, sponsored by Pfizer. Started Mar 2011; status: completed.

02

Drugs

meningococcal group B vaccine
03

Conditions

meningococcal disease

Beyond the preview

Go deeper on NCT01323270.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01323270.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call